Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics is a clinical-stage ophthalmic biotech company with a strong pipeline of AAV-based therapies targeting rare retinal diseases. With successful funding and a strong leadership team in ophthalmology, the company's lead candidate has shown promising results for treating inherited retinal diseases. However, potential challenges may arise in marketing and competition due to Viatris acquiring the rights to an effective eye dilation treatment discovered by Dr. Bennett, and there are also potential risks to Opus' patents and intellectual property.

Bears say

Opus Genetics is a clinical-stage biopharmaceutical company with a focus on developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. However, the limited clinical dataset across its lead IRD programs, lack of prior commercial launch experience, and ongoing net loss in financials indicate fundamental risks for the company. Furthermore, although Opus has a robust preclinical pipeline and potential expansion opportunities, the success of its two lead gene therapy programs remains crucial for achieving its target price. Overall, these risks and uncertainties lead to a negative outlook for the company's stock.

Opus Genetics (IRD) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Buy based on their latest research and market trends.

According to 11 analysts, Opus Genetics (IRD) has a Buy consensus rating as of May 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.